Veradigm Inc (NASDAQ:MDRX) faces a dip in share value following its announcement of below-consensus guidance for FY23.
The company forecasts FY23 revenue, based on GAAP standards, to fall between $608 million and $622 million, a range lower than the estimated $637.67 million. This projection includes a positive contribution of approximately $16 million from a customer litigation settlement, reflecting services rendered in previous years.
Adjusted EBITDA for FY23 is anticipated to be in the range of $122 million to $135 million, excluding the $16 million favorable customer litigation settlement and certain other legal settlements.
Analysts foresee adjusted EPS for FY23 to range between $0.79 and $0.88, compared to the consensus estimate of $0.89.
As of December 31, 2023, net cash is estimated to surpass $232 million, with cash and cash equivalents exceeding $440 million and debt standing at $208 million.
Lee Westerfield, Interim Chief Financial Officer, commented on the company’s financial position, stating, “The state of Veradigm is fundamentally healthy. Its financials rest on a solid foundation that is evident in its net cash position and its high-quality mix of recurring subscription revenue. We believe our fiscal health enables us to invest in strategic opportunities for growth, product initiatives for margin expansion, and share repurchases for returns to shareholders – all in all, fulfilling our mission to address unmet client needs for healthtech and to elevate ROI and shareholder value.”
Recent leadership changes within MDRX were also noted, occurring amid an investigation into financial reporting. Greg Garrison has assumed the role of Executive Chairman, while Shih-Yin Ho serves as interim CEO and Lee Westerfield as interim CFO. Former CEO Richard J. Poulton and CFO Leah S. Jones have resigned.